Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 161Recurrence 30Neoplasms, Plasma Cell 11Neoplasms 7Lymphoma, Mantle-Cell 7Paraproteinemias 6Lymphoma, Follicular 5Hematologic Neoplasms 5Lymphoma, Non-Hodgkin 4Immunoglobulin Light-chain Amyloidosis 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Diseases 3Carcinoma, Non-Small-Cell Lung 3Blood Protein Disorders 3Plasmacytoma 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Lymphoproliferative Disorders 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Acute 2Hemostatic Disorders 2Hemorrhagic Disorders 2Bone Marrow Neoplasms 2Amyloidosis 2Wilms Tumor 1

Interventions

sargramostim 2Monatide (IMS 3015) 2Granulocyte-Macrophage Colony-Stimulating Factor 2Azacitidine 2venetoclax 1ruxolitinib 1rucaparib 1olaparib 1cc-486 1Pemetrexed 1Observation 1Nivolumab 1Decitabine 1Cytarabine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pathologic Complete Response × Bortezomib × Clear all
NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Millennium Pharmaceuticals, Inc.

Phase 2 Completed
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡